NRXP NRX Pharmaceuticals Forecast, Technical & Fundamental Analysis
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases... Show more
NRXP is expected to report earnings to fall 75.00% to -10 cents per share on November 16
Q3'26
Est.
$-0.11
Q2'26
Missed
by $0.33
Q4'25
Beat
by $0.53
Q3'25
Beat
by $0.25
Q2'25
Missed
by $0.45
The last earnings report on August 17 showed earnings per share of -43 cents, missing the estimate of -11 cents. With 310.92K shares outstanding, the current market capitalization sits at 145.91M.
A.I. Advisor
published General Information
General Information
is a blank check company, which engages in a stock exchange, asset acquisition, stock purchase, and reorganization
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.
The Moving Average Convergence Divergence (MACD) for NRXP turned positive on August 13, 2026. Looking at past instances where NRXP's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NRXP's RSI Oscillator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on NRXP as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXP advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRXP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.490). P/E Ratio (0.358) is within average values for comparable stocks, (28.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.510). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (444.384).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
